FH535

FH535 is a **small molecule inhibitor** that targets both the Wnt/β-catenin signaling pathway and peroxisome proliferator-activated receptors (PPARγ and PPARδ)[1][3][5]. It acts as an antagonist of β-catenin/transcription factor (TCF/LEF) and PPAR pathways, inhibiting cell proliferation, migration, invasion, stemness (cancer stem cell populations), and growth of various cancer cell lines including colon, liver, breast, and pancreatic cancers, both in vitro and in vivo[1][2][4][5]. The molecule downregulates expression of genes involved in cell cycle progression and survival, such as cyclin D1 and survivin, as well as MMP-7, MMP-9, Snail, and vimentin[1][2][5]. FH535 is primarily used as a research tool to study Wnt/β-catenin and PPAR pathway inhibition in cancer biology and has not reached clinical approval or routine pharmaceutical use[3][5].

Other names

FH535FH-535FH 5352,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide